Better Buy: GlaxoSmithKline vs. Pfizer
Better Buy: GlaxoSmithKline vs. Pfizer Have all of the stocks of drugmakers in the coronavirus vaccine race delivered solid gains so far this year? Nope. GlaxoSmithKline‘s (NYSE:GSK) adjuvant is being used in three clinical-stage COVID-19 vaccine candidates, but its shares have plunged 20% year to date. Pfizer (NYSE:PFE) is arguably the clear leader in the race, […]
Read More